GlassScriptPhysician profile
David Kattan
NPI 1104873249
$1,620.69
in general payments reported to CMS, 2019-2025
21 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $78.59 · 2021: $122 · 2022: $174 · 2023: $223 · 2024: $523 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.11 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $538.41 | 2021-2025 | Micra, Mycarelink, Linq II |
| Novartis Pharmaceuticals Corporation | $248.87 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.87 | 2024-2025 | Farxiga, Lokelma, Airsupra |
| Janssen Pharmaceuticals, INC | $137.45 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $90.32 | 2019-2020 | |
| Lilly USA, LLC | $69.60 | 2023-2024 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $45.37 | 2023-2024 | Rexulti |
| Abbott Laboratories | $41.77 | 2020-2021 | |
| Novo Nordisk INC | $32.27 | 2024 | Ozempic |
| Lundbeck LLC | $27.18 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.95 | 2024 | |
| Janssen Scientific Affairs, LLC | $25.13 | 2021 | |
| Mannkind Corporation | $24.91 | 2025 | |
| Gilead Sciences, INC. | $23.91 | 2025 | |
| Dexcom, INC. | $23.29 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.41 | 2025 | Eliquis |
| Astellas Pharma US INC | $20.99 | 2019 | |
| Pfizer INC. | $19.72 | 2019 | |
| Abbvie INC. | $17.53 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.34 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.